Latest Outlook Therapeutics News & Updates

See the latest news and media coverage for Outlook Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Outlook Therapeutics

Late-stage biopharmaceutical company developing ophthalmic bevacizumab

outlooktherapeutics.com

Headquarters: Cranbury, United States
Founded year: 2011
Company type: Public company
Number of employees: 10–60

Last updated Today

Latest news about Outlook Therapeutics

Company announcements

Yesterday Outlook Therapeutics

Outlook Therapeutics wins appeal for ONS-5010

The appeal followed a formal dispute resolution process for their bevacizumab-vikg product.

May 15 Outlook Therapeutics

Outlook Therapeutics reports Q2 FY2026 financial results

The company provides a corporate update alongside its quarterly earnings.

April 21 Outlook Therapeutics

Outlook Therapeutics completes FDA dispute resolution meeting

The meeting concerned ONS-5010/LYTENAVA for wet AMD, a key step toward potential FDA approval.

April 7 Outlook Therapeutics

Outlook Therapeutics announces FDA acceptance of dispute resolution request

The FDA accepted the formal dispute resolution request for its bevacizumab-vikg candidate, used in ophthalmology.

Media coverage

Yesterday The Globe and Mail

Outlook Therapeutics Wins FDA Appeal for LYTENAVA Resubmission

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter Outlook Therapeutics ( (OTLK)) just unveiled an update. On May 26...

March 23 The National Law Review

Outlook Therapeutics Announces Proposed Public Offering

ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE)-- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for...

February 10 The Globe and Mail

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab...

2 June 2025 Kauppalehti

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom...

Never miss news about Outlook Therapeutics

Track Outlook Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Outlook Therapeutics competitors & trending companies

Browse news for competitors to Outlook Therapeutics and other trending companies.